Lynne Garrity-Ryan - Concepedia

Author

Lynne Garrity-Ryan

Paratek Pharmaceuticals (United States)ORCID

Also Known As

L. Garrity-Ryan, Lynne Garrity-Ryan, Lynne K. Garrity-Ryan

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Paratek Pharmaceuticals (United States)University of California, San Francisco West County Health Centers Andrzej Frycz Modrzewski Krakow University Lung Center of the Philippines

About

Lynne Garrity-Ryan is an author at Paratek Pharmaceuticals (United States) specializing in medicine, clinical microbiology, and microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	584
2	Natural Sciences	1	1	79
3	Biochemistry	1	1	79
4	Cell Biology	1	1	188
5	Cellular Physiology	1	1	188

Lynne Garrity-Ryan

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Omadacycline for Community-Acquired Bacterial Pneumonia Roman Stets, Monica Popescu, Joven Gonong, New England Journal of Medicine	2019	215
The Arginine Finger Domain of ExoT Contributes to Actin Cytoskeleton Disruption and Inhibition of Internalization of<i>Pseudomonas aeruginosa</i>by Epithelial Cells and Macrophages Lynne Garrity-Ryan, Barbara I. Kazmierczak, Robert Kowal, Infection and Immunity Protein SecretionInflammatory Lung DiseaseMicrobial PathogensLung InflammationCell Adhesion	2000	188
Omadacycline for Acute Bacterial Skin and Skin-Structure Infections William O’Riordan, Sinikka Green, J. Scott Overcash, New England Journal of Medicine	2019	148
Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects Mark H. Gotfried, Karolyn Horn, Lynne Garrity-Ryan, Antimicrobial Agents and Chemotherapy	2017	134
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial William O’Riordan, Carrie Cardenas, Elliot Shin, The Lancet Infectious Diseases Healthcare-associated InfectionSkin Structure InfectionsAcute Bacterial SkinAntimicrobial ChemotherapyInfection Control	2019	92
Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair Thomas Geiser, Barbara I. Kazmierczak, Lynne Garrity-Ryan, Cellular Microbiology Lung InflammationWound RepairImmunologyBacterial PathogenesisInflammation	2001	79
The ADP Ribosyltransferase Domain of <i>Pseudomonas aeruginosa</i> ExoT Contributes to Its Biological Activities Lynne Garrity-Ryan, Sasha H. Shafikhani, Priya Balachandran, Infection and Immunity BacteriologyImmunologyMolecular BiologyBiological ActivitiesInflammation	2003	79
Small Molecule Inhibitors of LcrF, a <i>Yersinia pseudotuberculosis</i> Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model Lynne Garrity-Ryan, Oak K. Kim, Joan-Miquel Balada-Llasat, Infection and Immunity Small Molecule InhibitorsMicrobial PathogensImmunologyAntimicrobial ChemotherapyBacterial Pathogens	2010	71
<i>N</i>-Hydroxybenzimidazole Inhibitors of the Transcription Factor LcrF in <i>Yersinia</i>: Novel Antivirulence Agents Oak K. Kim, Lynne Garrity-Ryan, Victoria J. Bartlett, Journal of Medicinal Chemistry	2009	60
Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function Jolene Kay Berg, Evan Tzanis, Lynne Garrity-Ryan, Antimicrobial Agents and Chemotherapy	2017	46

Page 1